Analysis Article • May 01

Over the last 7 days, the Clinical Research and Equipment industry has risen 7.5%, driven by gains from AddLife of 8.1%. In the same time, Promimic was down 10%. However, the industry is down 12% over the past year. Looking forward, earnings are forecast to grow by 19% annually.
Has the Swedish Clinical Research and Equipment Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Tue, 26 May 2026 | SEK 30.5b | SEK 14.6b | -SEK 849,175,077.00 | 38x | -35.9x | 2.1x |
| Thu, 23 Apr 2026 | SEK 31.2b | SEK 14.6b | -SEK 971,664,077.00 | 36.3x | -32.1x | 2.1x |
| Sat, 21 Mar 2026 | SEK 26.3b | SEK 14.6b | -SEK 838,374,077.00 | 31.2x | -31.4x | 1.8x |
| Mon, 16 Feb 2026 | SEK 27.0b | SEK 14.9b | -SEK 553,301,427.00 | 32.8x | -48.8x | 1.8x |
| Wed, 14 Jan 2026 | SEK 30.2b | SEK 14.9b | -SEK 744,515,427.00 | 47.2x | -40.5x | 2x |
| Fri, 12 Dec 2025 | SEK 33.0b | SEK 14.9b | -SEK 744,515,427.00 | 55x | -44.4x | 2.2x |
| Sun, 09 Nov 2025 | SEK 34.5b | SEK 14.7b | -SEK 748,598,012.00 | 57.3x | -46x | 2.3x |
| Tue, 07 Oct 2025 | SEK 35.2b | SEK 14.7b | SEK 61.3m | 58.2x | 575.5x | 2.4x |
| Thu, 04 Sep 2025 | SEK 34.5b | SEK 14.7b | SEK 60.9m | 55.9x | 566.6x | 2.4x |
| Sat, 02 Aug 2025 | SEK 35.8b | SEK 14.8b | SEK 186.0m | 57.8x | 192.3x | 2.4x |
| Mon, 30 Jun 2025 | SEK 46.7b | SEK 16.6b | SEK 405.8m | 68.5x | 115.1x | 2.8x |
| Wed, 28 May 2025 | SEK 45.5b | SEK 16.6b | SEK 401.3m | 72x | 113.4x | 2.7x |
| Fri, 25 Apr 2025 | SEK 42.1b | SEK 16.6b | SEK 580.4m | 47x | 72.5x | 2.5x |
| Sun, 23 Mar 2025 | SEK 37.2b | SEK 16.6b | SEK 614.3m | 38x | 60.5x | 2.2x |
| Tue, 18 Feb 2025 | SEK 43.9b | SEK 17.0b | -SEK 1,033,505,426.00 | 42.4x | -42.4x | 2.6x |
| Thu, 16 Jan 2025 | SEK 42.0b | SEK 16.7b | -SEK 1,152,911,426.00 | 43.6x | -36.4x | 2.5x |
| Sat, 14 Dec 2024 | SEK 44.1b | SEK 16.7b | -SEK 1,152,911,426.00 | 50.4x | -38.3x | 2.6x |
| Mon, 11 Nov 2024 | SEK 44.3b | SEK 16.8b | -SEK 948,072,426.00 | 50.7x | -46.8x | 2.6x |
| Wed, 09 Oct 2024 | SEK 47.0b | SEK 16.7b | -SEK 988,175,491.00 | 58.4x | -47.5x | 2.8x |
| Fri, 06 Sep 2024 | SEK 47.0b | SEK 16.7b | -SEK 987,374,492.00 | 59.5x | -47.6x | 2.8x |
| Sun, 04 Aug 2024 | SEK 47.4b | SEK 16.7b | -SEK 1,128,120,510.00 | 59.9x | -42x | 2.8x |
| Tue, 02 Jul 2024 | SEK 42.1b | SEK 16.3b | -SEK 1,188,686,510.00 | 54.5x | -35.4x | 2.6x |
| Thu, 30 May 2024 | SEK 41.5b | SEK 16.3b | -SEK 1,188,686,510.00 | 58.4x | -34.9x | 2.5x |
| Sat, 27 Apr 2024 | SEK 37.7b | SEK 16.2b | -SEK 1,246,589,705.00 | 36.2x | -30.2x | 2.3x |
| Mon, 25 Mar 2024 | SEK 38.8b | SEK 16.0b | -SEK 1,122,792,210.00 | 36x | -34.6x | 2.4x |
| Wed, 21 Feb 2024 | SEK 39.5b | SEK 16.1b | -SEK 1,406,407,350.00 | 45.7x | -28.1x | 2.5x |
| Fri, 19 Jan 2024 | SEK 36.2b | SEK 15.5b | -SEK 1,393,723,683.00 | 43.4x | -26x | 2.3x |
| Sun, 17 Dec 2023 | SEK 38.2b | SEK 15.5b | -SEK 1,393,723,683.00 | 47.6x | -27.4x | 2.5x |
| Tue, 14 Nov 2023 | SEK 30.9b | SEK 15.4b | -SEK 1,256,647,710.00 | 34.2x | -24.6x | 2x |
| Thu, 12 Oct 2023 | SEK 25.3b | SEK 15.1b | -SEK 1,134,516,711.00 | 35.7x | -22.3x | 1.7x |
| Sat, 09 Sep 2023 | SEK 29.2b | SEK 15.1b | -SEK 1,133,713,072.00 | 38.8x | -25.8x | 1.9x |
| Mon, 07 Aug 2023 | SEK 32.1b | SEK 15.1b | -SEK 213,871,038.00 | 46.7x | -150.2x | 2.1x |
| Wed, 05 Jul 2023 | SEK 37.1b | SEK 14.6b | -SEK 172,476,038.00 | 37.8x | -215.2x | 2.5x |
| Fri, 02 Jun 2023 | SEK 39.2b | SEK 14.6b | -SEK 173,602,038.00 | 39.7x | -225.6x | 2.7x |
-225.6x
How does Swedish Clinical Research and Equipment compare with similar industries?
| SE Market | 4.33% | |
| Healthcare | 5.83% | |
| Life Sciences | 7.51% | |
| Clinical Research and Equipment | 7.51% | |
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| ALIF B AddLife | SEK 153.70 | 8.1% +SEK 1.4b | -16.7% | PE33x | |
| MCAP MedCap | SEK 570.50 | 7.5% +SEK 600.8m | 28.1% | PE38x | |
| BICO BICO Group | SEK 19.32 | 8.8% +SEK 110.1m | -47.0% | PS0.9x | |
| GENO Genovis AB (publ.) | SEK 20.55 | 2.8% +SEK 36.3m | -22.2% | PE55.9x | |
| IDLDX IDL Diagnostics | SEK 0.52 | 9.9% +SEK 10.8m | -9.1% | PS2.2x |